PFPablo Moreno Franco

Pablo Moreno Franco

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pablo Moreno Franco has a total of 380 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Recognizing the limitations of CLIF-C ACLF in predicting outcomes following liver transplantation in acute-on-chronic liver failure

    by Jorge Sinclair De Frias, Lorenzo Olivero, Trisha Singh, Ananya Vasudhar, Shivang Bhakta, Terri Menser, Philip Lowman, Devang Sanghavi, Juan Canabal, Kristopher P. Croome, et al.

  • DNR Status and Hospital Mortality Measures Postmyocardial Infarction: Differentiating Preventable From Unpreventable Deaths in CMS Data

    by Benjamin D. Pollock, Annette M. Danks, Razvan M. Chirila, Pablo Moreno Franco, Jordan C. Ray, Sean C. Dowdy, Jennifer B. Cowart

    BACKGROUND: Publicly reported 30-day acute myocardial infarction (AMI) mortality rates are widely used to benchmark hospital performance. However, these measures may lack validity when they include deaths among patients with do-not-resuscitate (DNR) orders or those receiving palliative care—groups for whom mortality may be expected and goal-concordant. METHODS: We analyzed the national 100% Medicare Inpatient Standard Analytic File and Medicare Beneficiary Summary file to assess 30-day AMI mortality rates stratified by DNR status (absent, present-on-admission, and postadmission) and palliative care involvement. We then conducted a retrospective chart review of all 30-day AMI mortalities at a single academic medical center (2019–2025), applying Global Registry of Acute Coronary Events and a Palliative Performance Scale scores to identify unpreventable deaths, which we defined as a Global Registry of Acute Coronary Events >190.5 or Palliative Performance Scale ≤40%. Global Registry of Acute Coronary Events is a risk-stratification tool using clinical and laboratory variables whereas the Palliative Performance Scale is a bedside functional status and palliative care assessment quantifying patient’s self-care ability. RESULTS: Across n=467 259 total AMI encounters, mean (SD) age was 75.1 (10.5), and the population was 44% women. Thirty-day mortality was 10.4% (39 112/376 062) among patients without DNRs, 43.1% (26 181/60 719) in those with present-on-admission DNR, and 72.1% (21 984/30 478) in those with postadmission DNR. Among 9.2% (43 090/467 259) of encounters with palliative care, there was a 76.9% mortality rate (33 151/43 090). Hazard ratios for mortality were 5.25 (95% CI, 5.17–5.33) for present-on-admission DNR and 10.73 (95% CI, 10.55–10.91) for postadmission DNR as compared with encounters without DNRs. Among n=24 AMI mortalities at our institution, 71% (17/24) had DNRs, and 33% (8/24) met the unpreventable death criteria. CONCLUSIONS: The validity of 30-day AMI mortality metrics may be undermined by their inclusion of high-acuity, end-of-life patients, which may disincentivize hospitals from delivering appropriate, patient-centered care. Removal of DNR or palliative cases from performance measures should be explored to better identify opportunities for reducing preventable deaths.

  • Advanced circulatory support in oncologic patients with refractory cardiorespiratory failure.

    by Pablo Moreno Franco, Devang K Sanghavi, Pramod K Guru, Rosa Corro

    Advances in oncology and critical care have reshaped the profile of intensive care unit (ICU) patients, increasing encounters with cancer patients who develop refractory cardiorespiratory failure. The use of Extracorporeal Circulatory Support (ECLS), including extracorporeal membrane oxygenation (ECMO), has expanded beyond traditional indications, raising complex clinical, physiological, and ethical questions in oncologic populations. This chapter describes the current role of ECLS in critically ill patients with solid and hematologic malignancies, integrating available evidence on indications, patient selection, physiological considerations, complications, and reported outcomes. The discussion emphasizes the heterogeneity of study findings and the consistently limited observed outcomes. The chapter frames ECLS as a highly selective intervention, best guided by emerging cohort-level data, multidisciplinary evaluation, and careful alignment with oncologic trajectory, reversibility of organ failure, and patient-centered goals of care.

  • Open Access

    Comparison of SARS-CoV-2 Delta Versus Omicron Variant and Its Impact on Immunocompromised Versus Immunocompetent Population

    by Sadia Z. Shah, Parthkumar Satashia, Shahin Isha, Patrick Johnson, Katie Kunze, Abdul Moiz Khan, Jorge Sinclair, Rose Mary Attieh, Anirban Bhattacharyya, Ricardo Diaz Millian, et al.

    The Omicron variant of SARS-CoV-2 is associated with milder symptoms and lower hospitalization and mortality rates than Delta variants, although the impact of Omicron on immunocompromised patients, especially solid organ transplant (SOT) recipients, is still unclear. This study compares the hospitalization rate and outcomes between immunocompromised, immunocompetent, and SOT patients during the Delta and Omicron periods. We included adult patients who tested positive for SARS-CoV-2 on PCR or nasopharyngeal antigen test between 26 June 2021 to 8 September 2022, at our institution. A total of 12,401 COVID-19 patients were included, of which 11,055 were immunocompetent, and 1346 were immunocompromised (375 SOT recipients). Throughout the Delta and Omicron outbreaks, immunocompromised patients exhibited higher comorbidities and 30-day hospitalizations, but rates of mechanical ventilation and ICU-level care were like immunocompetent patients. During the Omicron wave, immunocompromised patients had higher unadjusted relative risk estimates (RR = 2.37, 95% CI 1.96–2.87, p < 0.05) than Delta (RR = 1.58, 95% CI 1.24–2.01, p < 0.05), with higher adjusted relative risk for hospitalization in Omicron (RR = 1.50, 95% CI 1.10–2.03, p = 0.01). Analyses show increased hospitalization risk in immunocompromised during the Omicron wave compared to the Delta wave, with no significant difference in hospitalization outcomes. The relative risk of hospitalization for SOT patients was higher in both waves.

  • Open Access

    Process Improvement Before Artificial Intelligence and Automation: Building Trust With the Understand-Transform-Sustain Framework

    by Alejandro Fabrega Gerbaud, Marta Berguido de la Guardia, Sandra C. Booth, LaRissa Adams, Matthew D. Cox, Kimberly Hunsinger, Nelly Tan, Melissa Gulden, Terri Menser, Ross Reichard, et al.

  • Open Access

    Comparison of SARS-CoV-2 Delta Versus Omicron Variant and Its Impact on Immunocompromised Versus Immunocompetent Population

    by Sadia Z. Shah, Parthkumar Satashia, Shahin Isha, Patrick Johnson, Katie Kunze, Abdul Moiz Khan, Jorge Sinclair, Rose Mary Attieh, Anirban Bhattacharyya, Ricardo Diaz Millian, et al.

    The Omicron variant of SARS CoV-2 is associated with milder symptoms and lower hospitalization and mortality rates than Delta variants, although the impact of Omicron on immunocompromised patients, especially Solid Organ Transplant (SOT) recipients, is still unclear. This study compares the hospitalization rate and outcomes between immunocompromised, immunocompetent, and SOT patients during the Delta and Omicron periods. We included adult patients who tested positive for SARS-CoV-2 on PCR or nasopharyngeal antigen test between June 26, 2021 to September 8, 2022, at our institution. 12,401 COVID-19 patients were included, of which 11,055 were immunocompetent, and 1,346 were immuno-compromised (375 SOT recipients). Throughout the Delta and Omicron outbreaks, immunocompromised patients exhibited higher comorbidities and 30-day hospitalizations, but rates of mechanical ventilation and ICU-level care were like immunocompetent patients. During the Omicron wave, immunocompromised patients had higher unadjusted relative risk estimates (RR=2.37, 95% CI 1.96-2.87, p< 0.05) than Delta (RR=1.58, 95% CI 1.24-2.01, p< 0.05) with higher adjusted relative risk for hospitalization in Omicron (RR=1.50, 95% CI 1.10-2.03, p=0.01). Analyses show increased hospitalization risk in immunocompromised during the Omicron wave compared to the Delta wave with no significant difference in hospitalization outcomes. The relative risk of hospitalization for SOT patients was higher in both waves.

  • Ketamine Use in Critically Ill Patients: Insights into Depressive Symptoms and Hemodynamic Changes

    by Vrutti Patel, Saurabh Sujanyal, Lekhya Raavi, Sophia G. Blumenfeld, Faiz Saleem, Said Bateh, Abby Hanson, Anek Jena, Shahin Isha, Katie L. Kunze, et al.

    Background: Ketamine has demonstrated efficacy in treatment-resistant depression, primarily in psychiatric or outpatient populations. Its use in ICU patients remains underexplored, with limited data beyond case reports and small series. This study evaluated the association between subanesthetic ketamine infusions and improvement in depressive symptoms and hemodynamic changes in ICU patients. Methods: We conducted a retrospective study of adults admitted to the ICU who received IV ketamine (0.3-0.75 mg/kg over 40 min on three consecutive days) for depressive symptoms. Changes in depressive symptoms were assessed using routine clinical documentation by physicians, nurses, and occupational and physical therapists. Hemodynamic parameters (blood pressure and heart rate) were recorded before and up to 120 min after infusion. The primary outcome was to evaluate depressive symptoms while the secondary outcome was to assess hemodynamic changes post transfusion. Results: Thirty-four patients met criteria, including 18 solid organ transplant recipients. Median age was 59 years; 61.8% were male. Ketamine was associated with improvement in apparent sadness (90.0% vs 52.2%, P < .05) and reported sadness (95.0% vs 59.1%, P < .05). In transplant recipients, improvement in apparent sadness remained significant (80.0% vs 41.7%, P < .05). Hemodynamic parameters remained stable; heart rate increased transiently at 15-30 min post-infusion, returning to baseline by 60-90 min. Adverse effects observed were anxiety (12.5%), restlessness and/or agitation (10.4%), and dissociation (8.16%). Conclusion: Subanesthetic ketamine improved specific depressive symptoms in critically ill ICU patients without significant hemodynamic instability. These findings support its potential as a rapid-acting antidepressant in the ICU, warranting further prospective trials.

  • Open Access

    Time-Driven Activity-Based Costing Methodology for Cost Savings in the EMOTE-TNK Study

    by Saptarshi Ghosh, Isabelle Delos Reyes, Carlos Perez Vega, C. Joseph Yelvington, Greg M. Worsowicz, Olivia Boykin, Josephine F. Huang, Lynda Christel, Tiffany M. Halstead, Lesia H. Mooney, et al.

  • Centralization is the solution to standardization: Donation after Circulatory Death organ recovery at a hospital-based Donor Care Unit

    by Kristopher P. Croome, C. Burcin Taner, Heather Markuson, Richard Howard, Brian Cruddas, Pablo Moreno Franco, Carla Venegas


  • Association of Pulmonary Artery Catheter Utilization with Outcomes in Patients with Cardiogenic Shock: A Retrospective Propensity-Matched Study

    by Shahin Isha, Akshat Banga, Ananya Biswas, Bekure Siraw, Tamal Basak, Mubashir Ayaz Ahmed, Juveriya Yasmeen, Titilope Olanipekun, Anirban Bhattacharyya, Devang K. Sanghavi, et al.

    Purpose: Despite the need for advanced hemodynamic monitoring, the role of the pulmonary artery catheter (PAC) in cardiogenic shock (CS) remains controversial due to conflicting evidence from previous studies. Material and Methods: This single-center retrospective study utilized the MIMIC-IV database to assess the impact of PAC use on 30-day in-hospital mortality and clinical outcomes in CS patients admitted between 2008 and 2019. Propensity score matching (PS) and inverse propensity treatment weighting (IPTW) were employed to adjust for baseline differences. The primary outcome was 30-day in-hospital mortality; secondary outcomes included hospital and ICU length of stay and complications. Cox proportional hazard ratio analyses were performed to evaluate the association between PAC use and mortality outcomes. Results: The final cohort consisted of 1940 adult CS patients, with 134 receiving PAC and 1806 not. PAC use significantly reduced 30-day in-hospital mortality (PS-matched HR 0.57, 95% CI: 0.39-0.83; IPTW HR 0.58, 95% CI: 0.35-0.96) but was associated with longer hospital stays (16.47 vs 12.37 days) and ICU stays (9.26 vs 7.52 days). Conclusion: PAC use in CS patients was associated with improved short-term survival but also with longer hospitalization and potential complications, underscoring the need for careful patient selection and further research.